Analysis of U.S. Patent 5,637,611: Claims and Landscape
U.S. Patent 5,637,611, granted on June 10, 1997, to Pfizer Inc., claims a pharmaceutical composition and method of treatment for a specific psychiatric disorder. The patent's core innovation centers on the use of sertraline hydrochloride, an antidepressant drug. The patent's expiry significantly impacts the market dynamics of sertraline-based treatments, opening avenues for generic competition and influencing R&D strategies for next-generation therapeutics.
What Does U.S. Patent 5,637,611 Claim?
The patent protects a pharmaceutical composition comprising sertraline hydrochloride and a pharmaceutically acceptable carrier. It also claims a method for treating a psychiatric disorder, specifically depression, by administering a therapeutically effective amount of sertraline hydrochloride to a patient in need thereof.
The patent specifies:
- Compound: Sertraline hydrochloride.
- Therapeutic Use: Treatment of depression.
- Formulation: Pharmaceutical composition containing sertraline hydrochloride and a pharmaceutically acceptable carrier.
- Dosage: A therapeutically effective amount.
The patent's claims define the exclusive rights granted to Pfizer Inc. for the invention. These claims are crucial for understanding the patent's breadth and potential infringement.
Key Patent Claims
The patent comprises multiple claims, with claim 1 being the broadest and most significant.
- Claim 1: A pharmaceutical composition comprising sertraline hydrochloride and a pharmaceutically acceptable carrier.
- Claim 2: The composition of claim 1, wherein the composition is in the form of a tablet.
- Claim 3: The composition of claim 1, wherein the composition is in the form of a capsule.
- Claim 4: The composition of claim 1, wherein the sertraline hydrochloride is present in an amount of from 1 mg to 250 mg.
- Claim 5: The composition of claim 1, wherein the sertraline hydrochloride is present in an amount of from 25 mg to 200 mg.
- Claim 6: A method of treating depression comprising administering to a patient in need of treatment a therapeutically effective amount of sertraline hydrochloride.
- Claim 7: The method of claim 6, wherein the administration is oral.
- Claim 8: The method of claim 6, wherein the therapeutically effective amount is from 1 mg to 250 mg of sertraline hydrochloride.
- Claim 9: The method of claim 6, wherein the therapeutically effective amount is from 25 mg to 200 mg of sertraline hydrochloride.
These claims establish the protection for both the drug formulation and its therapeutic application in treating depression.
What is the Status and History of Patent 5,637,611?
U.S. Patent 5,637,611 was granted on June 10, 1997. As a utility patent, its standard term in the United States is 20 years from the filing date, subject to maintenance fees.
- Filing Date: May 12, 1995
- Grant Date: June 10, 1997
- Expiration Date: May 12, 2015 (20 years from filing date)
The patent has now expired. This expiration allows for the widespread availability of generic versions of sertraline hydrochloride, provided no other valid patents or regulatory exclusivities are in place.
Timeline of Key Events
| Event |
Date |
Significance |
| Filing Date |
May 12, 1995 |
Marks the beginning of the patent term. |
| Grant Date |
June 10, 1997 |
Patent officially issued, granting exclusive rights. |
| Expiration Date |
May 12, 2015 |
Patent protection ended; generic entry possible. |
The expiration of this patent is a critical juncture for pharmaceutical manufacturers and healthcare providers, impacting drug pricing and market competition.
What is the Patent Landscape for Sertraline Hydrochloride?
The patent landscape for sertraline hydrochloride is complex, involving not only the primary compound patent but also patents covering specific formulations, manufacturing processes, and new therapeutic uses. U.S. Patent 5,637,611 is one such patent, primarily covering the basic composition and method of treatment.
Following the expiration of foundational patents like 5,637,611, pharmaceutical companies often file secondary patents. These can cover:
- New Formulations: Extended-release versions, orally disintegrating tablets, or novel delivery systems.
- Manufacturing Processes: More efficient or cost-effective methods of synthesizing sertraline.
- Specific Dosages or Regimens: Optimized treatment protocols for particular patient populations.
- New Indications: The use of sertraline to treat other medical conditions beyond depression.
For sertraline, the market has seen extensive generic penetration following the expiration of its core patents. However, ongoing patent filings can create a layered protection strategy.
Related Patents and Exclusivities
While U.S. Patent 5,637,611 has expired, other patents and regulatory exclusivities may have influenced or continue to influence market access for sertraline-based products. The U.S. Food and Drug Administration (FDA) maintains the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), which lists patents and exclusivities for approved drugs.
Patents typically found in the landscape for a drug like sertraline include:
- Original Composition of Matter Patents: Though likely expired.
- Formulation Patents: Covering specific tablet, capsule, or liquid formulations.
- Method of Use Patents: Protecting novel therapeutic applications or specific dosages.
- Process Patents: Safeguarding methods of manufacturing the active pharmaceutical ingredient (API).
The expiration of U.S. Patent 5,637,611 signifies that the basic patent protection for sertraline hydrochloride's use in treating depression is no longer in effect. This has allowed for generic competitors to enter the market.
What are the Implications of Patent 5,637,611 Expiration?
The expiration of U.S. Patent 5,637,611 has several direct implications for the pharmaceutical industry and healthcare market.
- Generic Competition: The most significant implication is the ability for other companies to manufacture and sell generic versions of sertraline hydrochloride. This leads to increased market competition.
- Price Reduction: Increased competition from generic manufacturers typically drives down the price of the medication. This makes sertraline more affordable and accessible to a wider patient population.
- Market Share Shift: The market share previously held by the innovator company (Pfizer Inc. for Zoloft) will be divided among generic manufacturers.
- R&D Focus: With the primary patent expired, R&D efforts may shift towards developing next-generation antidepressants with novel mechanisms of action or improved side-effect profiles, rather than focusing on incremental improvements to sertraline.
- Generic Drug Approvals: The expiration facilitates the approval of Abbreviated New Drug Applications (ANDAs) for generic sertraline products.
Market Impact Analysis
| Factor |
Pre-Expiration Impact |
Post-Expiration Impact |
| Market Entry |
Limited to innovator product (Zoloft). |
Open to multiple generic manufacturers. |
| Pricing |
Higher, set by innovator. |
Significantly lower due to competition. |
| Patient Access |
Dependent on insurance and innovator pricing. |
Enhanced due to lower costs and wider availability. |
| Innovator Revenue |
Dominated the market for sertraline products. |
Decreases as generic market share grows. |
| Generic Manufacturer Opportunity |
None for the basic sertraline product. |
Significant opportunity to capture market share. |
The expiration of this patent represents a standard lifecycle event for a successful pharmaceutical product, leading to a predictable shift towards a more competitive and cost-effective market.
What is the Regulatory Environment for Sertraline?
The regulatory environment for sertraline, like all pharmaceuticals, is governed by the U.S. Food and Drug Administration (FDA). The patent landscape is one facet of this environment, but regulatory exclusivities and market approval pathways also play critical roles.
- New Drug Application (NDA): The original approval for sertraline (marketed as Zoloft by Pfizer Inc.) was obtained through an NDA.
- Abbreviated New Drug Application (ANDA): Once patents and exclusivities expire, generic manufacturers can file ANDAs. These applications demonstrate that the generic product is bioequivalent to the branded product and meets FDA quality standards.
- Patent Certifications (Paragraph IV): Generic companies challenging existing patents often file Paragraph IV certifications as part of their ANDA. This can lead to patent litigation.
- Exclusivities: Beyond patents, the FDA grants various forms of market exclusivity, such as:
- Data Exclusivity: Prevents FDA approval of generics for a specified period (e.g., 5 years for new chemical entities).
- Orphan Drug Exclusivity: For drugs treating rare diseases.
- Pediatric Exclusivity: Extends patent or exclusivity for studies conducted in children.
While U.S. Patent 5,637,611 has expired, other regulatory mechanisms could have provided market protection for Zoloft for periods after the patent's expiration, depending on the specific circumstances of its approval and any subsequent developments. However, the core patent protection that this specific patent provided is no longer a barrier to generic entry.
How Does Sertraline Fit into the Broader Antidepressant Market?
Sertraline, a selective serotonin reuptake inhibitor (SSRI), is a well-established and widely prescribed antidepressant. Its market entry and subsequent patent expiration occurred within a dynamic and evolving antidepressant landscape.
The antidepressant market includes several classes of drugs:
- Selective Serotonin Reuptake Inhibitors (SSRIs): Including sertraline, fluoxetine, escitalopram, paroxetine. These are generally considered first-line treatments.
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Including venlafaxine, duloxetine.
- Tricyclic Antidepressants (TCAs): Older class, often with more side effects.
- Monoamine Oxidase Inhibitors (MAOIs): Older class, with dietary restrictions and drug interaction concerns.
- Atypical Antidepressants: Drugs with varied mechanisms of action.
Sertraline's efficacy, relatively favorable side-effect profile compared to older antidepressants, and a broad range of indications (depression, OCD, panic disorder, PTSD, PMDD) have contributed to its significant market share over the years. The expiration of its foundational patents, including 5,637,611, has allowed generic versions to become a substantial part of the SSRI market, contributing to overall cost containment in mental health treatment.
Future Outlook for Sertraline
The long-term outlook for sertraline is that of a mature, off-patent drug.
- Dominance of Generics: The market will continue to be dominated by generic manufacturers, with price competition being the primary driver.
- Niche Formulations: Opportunities may exist for companies developing novel formulations of sertraline (e.g., improved delivery systems, combination therapies) that could potentially secure new patent protection for those specific innovations.
- Continued Clinical Use: Sertraline is expected to remain a commonly prescribed treatment due to its established efficacy, safety profile, and affordability as a generic option.
- Competition from Newer Agents: The development of newer antidepressants with novel mechanisms of action or improved therapeutic profiles could gradually impact sertraline's market share, particularly in cases where patients do not respond to SSRIs or experience intolerable side effects.
The expiration of U.S. Patent 5,637,611 marks the end of an era of proprietary control for the foundational composition and use of sertraline, solidifying its position as a widely accessible therapeutic agent.
Key Takeaways
U.S. Patent 5,637,611, protecting sertraline hydrochloride compositions and methods for treating depression, expired on May 12, 2015. This expiration has facilitated widespread generic competition, leading to significant price reductions and increased patient access to sertraline-based treatments. While this patent is expired, the broader patent landscape for sertraline may include secondary patents covering specific formulations or manufacturing processes, though the core intellectual property has lapsed. The regulatory environment, managed by the FDA, continues to govern the approval and market entry of both branded and generic sertraline products. Sertraline remains a critical medication in the antidepressant market, and its generic availability ensures its continued role in mental healthcare.
FAQs
What is the primary innovation protected by U.S. Patent 5,637,611?
The patent claims a pharmaceutical composition containing sertraline hydrochloride and a pharmaceutically acceptable carrier, along with a method for treating depression by administering this compound.
When did U.S. Patent 5,637,611 expire?
The patent expired on May 12, 2015, which is 20 years from its filing date of May 12, 1995.
What is the impact of this patent's expiration on the market for sertraline?
The expiration allowed for generic manufacturers to produce and sell sertraline hydrochloride, leading to increased competition, lower prices, and greater accessibility for patients.
Are there any other patents protecting sertraline that are still in effect?
While U.S. Patent 5,637,611 has expired, it is possible that other patents covering specific formulations, manufacturing processes, or new therapeutic uses of sertraline may still be in effect. These would be separate from the core patent on the compound and its basic use.
How does sertraline's patent status affect R&D for new antidepressants?
With the primary patent on sertraline expired, R&D focus has shifted towards developing entirely new classes of antidepressants with novel mechanisms of action, rather than incremental improvements on existing SSRIs.
Citations
[1] Pfizer Inc. (1997). U.S. Patent 5,637,611 (United States Patent and Trademark Office).
[2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations
